Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Pacira BioSciences, Inc. (PCRX) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacira BioSciences, Inc. (PCRX) - free report >>
Image: Bigstock
OncoGenex Down on Poor Phase III Data on Lead Cancer Drug
Shares of OncoGenex Pharmaceuticals, Inc. were down 41% after the company announced disappointing data from its late-stage trial, AFFINITY, on custirsen in men with metastatic castrate-resistant prostate cancer (CRPC) whose disease has progressed after treatment with docetaxel.
Final analysis of the phase III trial showed that the candidate has failed to meet the primary endpoint of a statistically significant improvement in overall survival in patients treated with custirsen in combination with cabazitaxel/prednisone, compared to cabazitaxel/prednisone alone.
ONCOGENEX PHARM Price
ONCOGENEX PHARM Price | ONCOGENEX PHARM Quote
The results were a major blow to the company as custirsen is the only late-stage candidate in OncoGenex’s pipeline. Naturally, successful development of the candidate is crucial for the company’s growth prospects, given that it does not have any approved product in its portfolio yet. Consequently, OncoGenex plans to initiate discussions with the FDA to evaluate options for another phase III trial, ENSPIRIT, on custirsen, in combination with docetaxel, as second-line chemotherapy in patients with non-small cell lung cancer. The trial has already completed enrolment and hence an early analysis will help the company determine the path going forward and conserve resources.
Meanwhile, OncoGenex is exploring strategic alternatives for its business and has engaged MTS Health Partners, LP as its advisor to assist with the same. Apart from custirsen, other candidates in the company’s oncology pipeline include apatorsen (phase II) and OGX-225 (pre-clinical development).
Investors interested in the health care sector may consider stocks like Pacira Pharmaceuticals, Inc. (PCRX - Free Report) , Corcept Therapeutics Incorporated (CORT - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . All three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>